This audio is automatically generated. Do us know if you have comments.
Abbvie plans to spend $ 195 million to build a new installation to produce active pharmaceutical ingredients in its northern northern Chicago city, Illinois.
Construction will begin in the fall and the site should be completely operational in 2027, said Abbvie Tuesday. The installation will help the company to produce current and future medicines in neuroscience, immunology and oncology.
The new investment is part of a larger commitment of more than $ 10 billion in capital investments in the United States for the next decade. Abbvie’s CEO, Rob Michael, announced the plan in April, linking it to the growth of the volume planned and expansion in areas that include obesity drugs.
Drugs manufacturers have rushed to cause their United States manufacturing investments in the midst of fee threats to President Trump’s pharmaceutical imports. More recently, Trump said that these rates could rise to 250%, starting small and then increased for a period and a half.
Abbvie’s overall commitment is relatively small compared to some other large pharmaceutical companies; Johnson & Johnson promised $ 55 billion for four years, and Astrazeneca pledged to spend $ 50 billion on manufacturing and research in the United States until 2030. Eli Lilly in February increased his $ 50 billion $ 23 billion investment promise, including commitments made in the years since 2020.
However, many of the ads in the industry do not have details where all the money will go. Abbvie said that the new North Chicago facility will add to a manufacturing footprint that currently supports more than 6,000 North -Americans in 11 places. The company employs more than 11,000 people in Illinois.
